We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-15.04%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$185M
AUM Growth
-$43.2M
Cap. Flow
+$19.8M
Cap. Flow %
10.73%
Top 10 Hldgs %
66.67%
Holding
76
New
13
Increased
20
Reduced
16
Closed
22
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.6 years
Avg Time Held Equity only
0.6 years
Top 10 Avg Time Held Equity only
0.5 years
Top 20 Avg Time Held Equity only
0.6 years

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$9.46M
2
ZGNX
Zogenix, Inc.
ZGNX
+$5.9M
3
RCM icon
R1 RCM Inc. Common Stock
RCM
+$5.74M
4
AERI
Aerie Pharmaceuticals
AERI
+$5.26M
5
AMRN icon
Amarin Corp
AMRN
+$4.88M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$7.55M
2
SAGE icon
Sage Therapeutics
SAGE
+$4.05M
3
ABT icon
Abbott
ABT
+$3.07M
4
MDT icon
Medtronic
MDT
+$2.65M
5
ANAB icon
AnaptysBio
ANAB
+$2.25M

Sector Composition

Rank Sector Weight
1 Healthcare 87.02%
2 Industrials 10.11%
3 Miscellaneous 2.35%
4 Real Estate 0.52%
5 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
APLS icon
26
DELISTED
Apellis Pharmaceuticals
APLS
$1.41M 0.76%
106,880
+6,585
+7% +$101K
2018 Q2
2 quarters
LOXO
27
DELISTED
Loxo Oncology, Inc
LOXO
$1.4M 0.76%
+10,000
New +$1.52M
2018 Q4
0 quarters
BSTC
28
DELISTED
BioSpecifics Technologies Corp.
BSTC
$1.33M 0.72%
22,000
+100
+0.5% +$5.97K
2018 Q3
1 quarter
BCRX icon
29
BioCryst Pharmaceuticals
BCRX
$1.99B
$1.32M 0.72%
163,959
+15,000
+10% +$117K
2017 Q4
4 quarters
XENE icon
30
Xenon Pharmaceuticals
XENE
$3.24B
$1.29M 0.7%
205,104
-4,635
-2% -$41.2K
2018 Q3
1 quarter
ARRY icon
31
DELISTED
Array Biopharma Inc
ARRY
$1.29M 0.7%
90,412
+30,000
+50% +$455K
2017 Q4
4 quarters
FOMX
32
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.06M 0.57%
294,660
+20,843
+8% +$90.6K
2018 Q1
3 quarters
AFMD icon
33
DELISTED
Affimed
AFMD
$1.04M 0.57%
33,577
-9,696
-22% -$361K
2018 Q1
3 quarters
CTRE icon
34
CareTrust REIT
CTRE
$8.64B
$956K 0.52%
51,264
– –
2017 Q4
4 quarters
ASND icon
35
Ascendis Pharma A/S
ASND
$14.8B
$956K 0.52%
15,254
-3,800
-20% -$239K
2017 Q4
4 quarters
TCDA
36
DELISTED
Tricida, Inc. Common Stock
TCDA
$956K 0.52%
40,522
+16,400
+68% +$471K
2018 Q3
1 quarter
ARQL
37
DELISTED
Arqule Inc
ARQL
$955K 0.52%
344,618
+55,000
+19% +$210K
2018 Q2
2 quarters
PBYI icon
38
Puma Biotechnology
PBYI
$507M
$861K 0.47%
42,301
+20,630
+95% +$619K
2017 Q4
4 quarters
SAGE icon
39
DELISTED
Sage Therapeutics
SAGE
$792K 0.43%
8,271
-35,350
-81% -$4.05M
2018 Q1
3 quarters
ELV icon
40
Elevance Health
ELV
$92.9B
$604K 0.33%
2,300
– –
2018 Q1
3 quarters
FOLD icon
41
DELISTED
Amicus Therapeutics
FOLD
$601K 0.33%
62,750
-17,000
-21% -$187K
2018 Q3
1 quarter
NTRA icon
42
Natera
NTRA
$56.7B
$552K 0.3%
+39,539
New +$722K
2018 Q4
0 quarters
CNC icon
43
Centene
CNC
$34.2B
$496K 0.27%
8,600
– –
2018 Q1
3 quarters
ALBO
44
DELISTED
Albireo Pharma Inc
ALBO
$442K 0.24%
18,029
– –
2018 Q1
3 quarters
DRNA
45
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$439K 0.24%
41,074
-10,000
-20% -$132K
2018 Q2
2 quarters
LAB icon
46
Standard BioTools
LAB
$247M
$435K 0.24%
+50,455
New +$393K
2018 Q4
0 quarters
CBAY icon
47
DELISTED
Cymabay Therapeutics
CBAY
$371K 0.2%
47,096
-25,000
-35% -$238K
2018 Q2
2 quarters
IVC
48
DELISTED
Invacare Corporation
IVC
$318K 0.17%
73,902
-35,000
-32% -$309K
2017 Q4
4 quarters
SPNE
49
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$282K 0.15%
15,459
-15,440
-50% -$261K
2017 Q4
4 quarters
TGTX icon
50
TG Therapeutics
TGTX
$8.26B
$267K 0.14%
65,000
– –
2018 Q1
3 quarters
1
2
3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q4 2018 Portfolio in Review

As of Q4 2018, Eversept Partners held 76 positions worth $185M, down 19% from $228M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Eversept Partners deployed $19.8M of net new capital in Q4 2018, opening 13 new positions and adding to 20 existing holdings. Its largest new stake was Fate Therapeutics: 165,000 shares worth $2.12M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 79% a quarter earlier, followed by Industrials and Miscellaneous.

On the sell side, the largest reduction was Merck, an estimated $7.55M trimmed.

  • Eversept Partners's largest Q4 2018 buy was Fate Therapeutics: 165,000 shares worth $2.12M.
  • Eversept Partners added most to GSK in Q4 2018, an estimated $9.46M increase.
  • Eversept Partners's biggest Q4 2018 reduction was Merck, cutting an estimated $7.55M.
  • Eversept Partners fully exited Medtronic in Q4 2018, selling an estimated $2.65M.
  • Eversept Partners's ten largest holdings make up 67% of its $185M portfolio in Q4 2018.
  • Eversept Partners opened 13 new positions and closed 22 in Q4 2018.
  • Eversept Partners's portfolio value fell 19% quarter-over-quarter to $185M.

Based on Eversept Partners's 13F filing for Q4 2018, filed 13 Feb 2019.